$6.26 Million in Sales Expected for Regenxbio Inc (NASDAQ:RGNX) This Quarter

Wall Street brokerages expect that Regenxbio Inc (NASDAQ:RGNX) will post $6.26 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Regenxbio’s earnings. The lowest sales estimate is $5.31 million and the highest is $7.20 million. Regenxbio reported sales of $5.31 million during the same quarter last year, which indicates a positive year over year growth rate of 17.9%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Regenxbio will report full year sales of $42.20 million for the current financial year, with estimates ranging from $13.26 million to $76.35 million. For the next fiscal year, analysts expect that the firm will report sales of $162.82 million, with estimates ranging from $157.26 million to $172.40 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Regenxbio.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.46. Regenxbio had a negative return on equity of 15.39% and a negative net margin of 88.57%. The business had revenue of $7.88 million for the quarter, compared to the consensus estimate of $5.45 million. During the same quarter in the previous year, the company posted $0.30 EPS. The company’s revenue was down 80.3% compared to the same quarter last year.

A number of analysts have issued reports on RGNX shares. Morgan Stanley set a $84.00 price objective on Regenxbio and gave the stock a “buy” rating in a research note on Monday, July 15th. BidaskClub downgraded Regenxbio from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 15th. TheStreet downgraded Regenxbio from a “c” rating to a “d+” rating in a research note on Thursday, May 9th. Chardan Capital set a $150.00 price objective on Regenxbio and gave the stock a “buy” rating in a research note on Wednesday. Finally, Svb Leerink raised Regenxbio from an “underperform” rating to a “market perform” rating and reduced their price objective for the stock from $38.00 to $37.00 in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Regenxbio currently has an average rating of “Buy” and a consensus price target of $79.56.

NASDAQ:RGNX traded down $1.14 during trading hours on Friday, reaching $33.93. The stock had a trading volume of 347,414 shares, compared to its average volume of 607,527. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.58 and a current ratio of 14.58. Regenxbio has a 52 week low of $33.73 and a 52 week high of $83.45. The company has a 50 day moving average price of $43.70 and a two-hundred day moving average price of $49.09. The stock has a market capitalization of $1.35 billion, a PE ratio of 14.26 and a beta of 0.71.

In other news, insider Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $52.54, for a total transaction of $788,100.00. Following the transaction, the insider now owns 261,000 shares of the company’s stock, valued at approximately $13,712,940. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Patrick J. Christmas sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $52.99, for a total value of $264,950.00. Following the transaction, the senior vice president now directly owns 8,006 shares in the company, valued at approximately $424,237.94. The disclosure for this sale can be found here. In the last three months, insiders have sold 73,000 shares of company stock worth $3,508,800. Corporate insiders own 13.80% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Regenxbio by 3.5% during the 2nd quarter. BlackRock Inc. now owns 5,047,103 shares of the biotechnology company’s stock valued at $259,270,000 after purchasing an additional 169,888 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Regenxbio by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 3,449,874 shares of the biotechnology company’s stock valued at $177,220,000 after purchasing an additional 44,452 shares during the last quarter. Redmile Group LLC increased its position in shares of Regenxbio by 4.8% during the 1st quarter. Redmile Group LLC now owns 1,420,342 shares of the biotechnology company’s stock valued at $81,400,000 after purchasing an additional 65,600 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Regenxbio by 10.0% during the 1st quarter. JPMorgan Chase & Co. now owns 1,205,445 shares of the biotechnology company’s stock valued at $69,085,000 after purchasing an additional 109,620 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Regenxbio by 1.9% during the 2nd quarter. Northern Trust Corp now owns 426,105 shares of the biotechnology company’s stock valued at $21,889,000 after purchasing an additional 7,922 shares during the last quarter. 81.07% of the stock is currently owned by hedge funds and other institutional investors.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Story: What is a Stop Order?

Get a free copy of the Zacks research report on Regenxbio (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.